Varenicline as a Smoking Cessation Tool for Long-Term Recovery
Original Air Date: February 24th 2:30 – 3:30 pm ET
Varenicline, an FDA-approved prescription smoking cessation aid, is an effective evidence-based treatment for reducing tobacco use among individuals with mental health and substance use challenges. Supporting tobacco cessation, such as the use of pharmacological supports, in substance use treatment has been shown to enhance long-term recovery outcomes overall.
Join the National Behavioral Health Network for Tobacco and Cancer Control, and the Behavioral Health and Wellness Program at the University of Colorado Anschutz Medical Campus on February 24 from 2:30–3:30 p.m. ET for a deep-dive into the benefits, challenges and emerging trends around the use of varenicline for tobacco cessation in individuals with mental health and substance use challenges.
By joining this webinar, you will:
- Explore the role of FDA-approved pharmacological treatments for smoking cessation.
- Learn about the benefits of varenicline as a first-line cessation medication for individuals with serious mental illness (SMI).
- Examine the evidence base regarding using varenicline in combination with other cessation medications and behavioral strategies.
- Gain practical tools to initiate conversations with patients around the use of varenicline for smoking cessation.
The webinar features Chad Morris, Ph.D., Professor of Psychiatry and Director of the Behavioral Health & Wellness Program, University of Colorado, Anschutz Medical Campus.
This event is co-hosted by the Behavioral Health and Wellness Program at the University of Colorado Anschutz Medical Campus, and the National Behavioral Health Network for Tobacco & Cancer Control with support from the Centers for Disease Control and Prevention.